McDavid Stilwell - 31 Dec 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Financial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for McDavid Stilwell
Issuer symbol
CHRS
Transactions as of
31 Dec 2023
Net transactions value
-$61,405
Form type
4
Filing time
03 Jan 2024, 16:42:10 UTC
Previous filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Tax liability $61,405 -18,440 -20% $3.33 75,305 31 Dec 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2 Includes 4,826 shares acquired on November 15, 2023, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan and includes the cancellation of 13,333 restricted stock units.